Correlation Engine 2.0
Clear Search sequence regions
Bookmark Forward

QuickView for ketamine (compound)


PubChem
Name: Ketamine
PubChem Compound ID: 15851
Description: A cyclohexanone derivative used for induction of anesthesia. Its mechanism of action is not well understood, but ketamine can block NMDA receptors (RECEPTORS, N-METHYL-D-ASPARTATE) and may interact with sigma receptors.
Molecular formula: C13H17Cl2NO
Molecular weight: 274.186 g/mol
Synonyms:
Ketavet; Ketalar (TN); Ketaset; EINECS 217-484-6; Ketalar; HSDB 2180; 100477-73-4; CN-52,372-2; Cyclohexanone, 2-(2-chlorophenyl)-2-(methylamino)-, hydrochloride, (+-)-; 96448-41-8.
show more »
DrugBank
Identification
Name: Ketamine
Name (isomeric): DB01221
Drug Type: small molecule
Description: A cyclohexanone derivative used for induction of anesthesia. Its mechanism of action is not well understood, but ketamine can block NMDA receptors (RECEPTORS, N-METHYL-D-ASPARTATE) and may interact with sigma receptors.
Synonyms:
Ketamine Base; (S)-Ketamine; Ketamine HCL; (S)-(-)-Ketamine; l-Ketamine; (-)-Ketamine; CI 581 base
Brand: Ketalar base, Ketanest, Esketamine, CLSTA 20, Ketalar, Ketolar, Ketaject
Category: General Anesthetics, Analgesics, Anesthetics, Dissociative, Excitatory Amino Acid Antagonists
CAS number: 6740-88-1
Pharmacology
Indication: For use as the sole anesthetic agent for diagnostic and surgical procedures that do not require skeletal muscle relaxation.
Pharmacology:
Ketamine is a rapid-acting general anesthetic producing an anesthetic state characterized by profound analgesia, normal pharyngeal-laryngeal reflexes, normal or slightly enhanced skeletal muscle tone, cardiovascular and respiratory stimulation, and occasionally a transient and minimal respiratory depression. Ketamine is indicated as the sole anesth...
show more »
Mechanism of Action:
Ketamine has several clinically useful properties, including analgesia and less cardiorespiratory depressant effects than other anaesthetic agents, it also causes some stimulation of the cardiocascular system. Ketamine has been reported to produce general as well as local anaesthesia. It interacts with N-methyl-D-aspartate (NMDA) receptors, opioid ...
show more »
Absorption: Rapidly absorbed following parenteral administration.
Biotransformation: Hepatic.
Half Life: 2.5-3 hours.
Affected organisms: Humans and other mammals
Interactions
Drug interaction:
ThiotepaThiotepa, a strong CYP2B6 inhibitor, may decrease the metabolism and clearance of Ketamine, a CYP2B6 substrate. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Ketamine if Thiotepa is initiated, discontinued or dose changed.
VoriconazoleVoriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of ketamine by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of ketamine if voriconazole is initiated, discontinued or dose changed.
TelithromycinTelithromycin may reduce clearance of Ketamine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Ketamine if Telithromycin is initiated, discontinued or dose changed.
MemantineIncreased risk of CNS adverse effects with this association
TolbutamideTolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Ketamine. Consider alternate therapy or monitor for changes in Ketamine therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed.

Targets


Enzymes


Transporters